OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-related Macular Degeneration
By, Admin1 min read
Share
OliX Pharmaceuticals Inc a leading developer of RNAi therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
